The second suggested that metformin is not only a drug of choice for the treatment of type 2 diabetes mellitus in the clinical setting but can also act as an activator of AMPK [72], as has recently been confirmed [73]. Here, PRKAA2 is linked to type 2 diabetes mellitus.